Intrathecal administration of tumor-infiltrating lymphocytes is well tolerated in a patient with leptomeningeal disease from metastatic melanoma: A case report

Lignende værker

• Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2
  af: Glitza, Isabella C, et al.
  Udgivet: (2018)
• IMCT-07 THERAPEUTIC OUTCOMES OF INTRATHECAL INTERLEUKIN-2 IN METASTATIC MELANOMA PATIENTS WITH LEPTOMENINGEAL DISEASE (LMD)
  af: Glitza, Isabella C., et al.
  Udgivet: (2015)
• Utilizing T-cell activation signals 1, 2 and 3 for tumor-infiltrating lymphocytes (TIL) expansion: the advantage over the sole use of interleukin-2 in cutaneous and uveal melanoma
  af: Tavera, René J., et al.
  Udgivet: (2018)
• PD-1 and BTLA and CD8(+) T-cell “exhaustion” in cancer: “Exercising” an alternative viewpoint
  af: Haymaker, Cara, et al.
  Udgivet: (2012)
• The beneficial effects of a gas-permeable flask for expansion of Tumor-Infiltrating lymphocytes as reflected in their mitochondrial function and respiration capacity
  af: Forget, Marie-Andrée, et al.
  Udgivet: (2015)